Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative drugs function by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By activating GLP-1 receptors in the pancreas, these agents boost insulin release and reduce glucagon output,

The management of diabetes has become with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising strategies for controlling blood sugar levels and may improve the lives of individuals living with diabetes. This novel cl